Top Qs
Timeline
Chat
Perspective
5-MeO-MiPT
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
5-MeO-MiPT, also known as 5-methoxy-N-methyl-N-isopropyltryptamine or by its nickname Moxy, is an atypical psychedelic drug of the tryptamine and 5-methoxytryptamine families.[1][3] It has unique and unusual effects compared to other psychedelic tryptamines.[1][3][5] At low doses, its effects include stimulation, tactile and sexual enhancement, some MDMA-like entactogenic effects, and introspective and mild perceptual changes with little or no psychedelic visuals or time dilation, whereas at higher doses, it produces 5-MeO-DMT-like classical psychedelic effects.[1][3][5] It is usually taken orally or smoked.[1]
The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, among others.[6][7][8] It is closely related in chemical structure and effects to 5-MeO-DiPT, and is also related to other tryptamines like 5-MeO-DMT, 4-HO-MiPT, and MiPT.[1][3][5]
5-MeO-MiPT was first described in the literature by Alexander Shulgin and David Repke and colleagues in 1985.[3][9] It was later described by Shulgin in greater detail in his 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] The United States Drug Enforcement Administration (DEA) unsuccessfully tried to ban 5-MeO-MiPT in the 2020s.[3] This effort was opposed by the psychedelic community.[3]
Remove ads
Use and effects
Summarize
Perspective
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the dose of 5-MeO-MiPT as 4 to 6 mg orally and 12 to 20 mg smoked.[1] A wider recreational dose range of 0.5 to 20 mg or more orally has also been reported however.[10][3][4] Oral doses of 1 to 3 mg have been described as light, 3 to 8 mg as common or moderate, and 8 to 12 mg as strong.[4] Its onset of action when taken orally is described as very rapid, occurring within 15 to 45 minutes, peak effects appear to occur after around 1 to 2 hours, and its duration as 4 to 6 hours.[1] However, other sources state its duration as 3 to 8 hours.[3][4]
5-MeO-MiPT has been described as having unique and unusual effects relative to other psychedelic tryptamines.[1][3][5] The effects of 5-MeO-MiPT differ depending on whether it is taken orally or smoked and are highly dose-dependent.[1][3] When taken orally at relatively low doses like 4 to 6 mg, it is usually described as not producing psychedelic visuals or related sensory effects and as producing only hints of time dilation.[1][3] However, it is said to produce a stoned state that includes an ease of interpretive fantasy, dream-like perception, intense conceptual thought and philosophical thinking, and mild perceptual effects like altered depth perception, minor wave pattern in peripheral vision, and slightly enhanced auditory acuity.[1] Moreover, the drug is described as producing stimulation, greatly enhanced tactile sensation and eroticism, enhanced music appreciation, tingling, shakes, and mild motor impairment.[1][3] Its head space is described as relatively "shallow", less confusing, and more easily tolerated compared to classical psychedelics.[3] Its effects have been described by users variably as both pleasant and negative.[1][3]
When smoked, 5-MeO-MiPT is described as having effects similar in many regards to those of 5-MeO-DMT.[1] These effects of smoked 5-MeO-MiPT include a powerful rush (but less intense than 5-MeO-DMT), loss of coherent thought, not much in the way of visuals, closed-eye visuals of moving and colored geometric patterns, intense waves of mental imagery of emotionally infused memories, impressive recall of early memories, intense depersonalization or disorientation of the normal sense of being a person in a body, loss of immediate contact with surroundings, emotional lability including laughing, crying, and vocal outbursts, groaning, writhing, shaking around, and general disorientation.[1] It is described as having a very rapid onset, with the peak phase lasting less than 30 minutes and waves continuing for up to a few hours.[1] It was described by one user as feeling like a hybrid between diethyltryptamine (DET) and 5-MeO-DMT.[1]
5-MeO-MiPT is also known by its nickname "Moxy"[3] and is closely related both in terms of chemical structure and effects to 5-MeO-DiPT (also known as "Foxy Methoxy").[5][1] These two serotonergic tryptamines at low doses have been described as very aphrodisiac and much more stimulant-like and party drugs than classical psychedelics.[5] However, they have been described as not innately aphrodisiac, but instead as enhancing tactile sensation in a way that lends itself to sex.[5] Matthew Baggott has described 5-MeO-MiPT as having some MDMA-like entactogenic effects at low doses, including tactile enhancement and feelings of empathy, intimacy, and closeness with others, and as producing classical psychedelic effects at higher doses.[11]
In addition to its use on its own, 5-MeO-MiPT is employed as a component of the MDMA-mimicking Borax combo.[3][12][13][14]
Remove ads
Side effects
Adverse effects of 5-MeO-MiPT include loss of appetite and insomnia.[1] Low-dose 5-MeO-MiPT did not cause any serious histopathological effects on the liver, kidney, and brain. High doses induce apoptotic cell death through caspase activity especially in some parts of the organs.[15] There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.[3]
Interactions
Pharmacology
Summarize
Perspective
Pharmacodynamics
The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-MiPT is thought to result primarily from serotonin 5-HT2A receptor agonism, although additional mechanisms of action such as inhibition of monoamine oxidase (MAO) might also be involved.[9][16] In addition to the serotonin 5-HT2A receptor, 5-MeO-MiPT also potently binds to and/or activates other serotonin receptors, such as the serotonin 5-HT1A, 5-HT2B, and 5-HT2C receptors.[6]
In addition to the serotonin receptors, 5-MeO-MiPT has also been found to show significant affinity to the serotonin transporter (SERT) and norepinephrine transporter (NET), thereby acting as a moderately potent serotonin–norepinephrine reuptake inhibitor (SNRI).[8] However, subsequent research contradicted the preceding findings and found that 5-MeO-MiPT did not significantly bind to or inhibit the human monoamine transporters.[6] The drug is also inactive as a monoamine releasing agent.[16]
Remove ads
Chemistry
5-MeO-MiPT is in a class of compounds commonly known as tryptamines, and is the N-methyl-N-isopropyl homologue of 5-MeO-DMT. The full name of the chemical is 5-methoxy-N-methyl-N-isopropyltryptamine.
Analogues
Analogues of 5-MeO-MiPT include MiPT, 5-MeO-DMT, 5-MeO-DiPT, and 5-MeO-MET, among others.
Detection
5-MeO-MiPT causes the ehrlich reagent to turn purple then fade to faint blue. It causes the marquis reagent to go yellow through to black.[19]
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from protestkit.
Remove ads
Society and culture
Legal status
The legal status of 5-MeO-MiPT differs internationally. It is not scheduled in Canada,[20] and in Luxembourg it is not listed among prohibited substances, making it legal there.[21] In the United States, it is unscheduled at the federal level,[22] but may be treated as an analog of 5-MeO-DiPT under the Federal Analog Act. At the state level, “5-Methoxy-N-methyl-N-isopropyltryptamine” is classified as a Schedule I controlled substance in Florida, prohibiting its purchase, sale, or possession.[23]
In other jurisdictions, control is stricter. As of September–October 2015, China lists 5-MeO-MiPT as a controlled substance.[24] Finland includes it in its decree banning certain psychoactive substances from the consumer market.[25] In the United Kingdom, it is classified as a Class A drug along with most ethers of ring-hydroxy tryptamines.[citation needed]
Remove ads
Research
5-MeO-MiPT, under the developmental designation MSD-001, is being investigated for potential medical use. As of September 2024, it has received regulatory approval to begin Phase I clinical trials in healthy individuals in both the United States and the European Union.[26][27][28][29] The compound is being developed by Mindstate Design Labs, which uses an AI platform named Osmanthus to analyze subjective experience reports and identify relationships between receptor targets and psychoactive effects. MSD-001 is being developed as a neutral psychoactive base intended for combination with other compounds selected based on biochemical insights derived from this analysis.[30][31][32][33]
Remove ads
See also
- Substituted tryptamine
- 5-MeO-DiPT
- ASR-3001 (5-MeO-iPALT)
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads